aTyr Pharma Dividends and Buybacks

Dividend criteria checks 0/6

aTyr Pharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-8.3%

Buyback Yield

Total Shareholder Yield	-8.3%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ATYR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATYR's dividend payments have been increasing.

Dividend Yield vs Market

aTyr Pharma Dividend Yield vs Market

How does ATYR dividend yield compare to the market?
Segment	Dividend Yield
Company (ATYR)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.5%
Industry Average (Biotechs)	1.6%
Analyst forecast (ATYR) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate ATYR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATYR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ATYR's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ATYR has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/03 08:44
End of Day Share Price	2025/02/28 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

aTyr Pharma, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Birchenough	BMO Capital Markets Equity Research
Prakhar Agrawal	Cantor Fitzgerald & Co.
Ilya Zubkov	Freedom Broker

aTyr Pharma Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

New minor risk - Share price stability

New minor risk - Profitability

Price target decreased by 12% to US$20.00

New major risk - Shareholder dilution

Forecast to breakeven in 2027

aTyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors

aTyr Pharma, Inc. Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

New major risk - Financial position

New minor risk - Financial position

New minor risk - Profitability

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

New minor risk - Share price stability

Independent Director recently bought US$185k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Independent Chairman of the Board recently bought US$88k worth of stock

Price target increased by 8.8% to US$24.60

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Consensus revenue estimates decrease by 85%, EPS upgraded

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates fall by 70%

New minor risk - Profitability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Consensus revenue estimates fall by 93%

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Consensus EPS estimates upgraded to US$0.90 loss

Price target increased by 17% to US$23.25

Consensus EPS estimates upgraded to US$1.03 loss

Independent Director recently bought US$450k worth of stock

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Consensus revenue estimates fall by 25%

Price target increased by 8.9% to US$22.00

Consensus revenue estimates decrease by 25%

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Consensus forecasts updated

Price target decreased to US$21.20

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Consensus revenue estimates fall by 67%

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma gains with FDA Fast Track status for lead asset

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$17.33

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

Consensus revenue estimates fall by 33%

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Price target increased to US$19.25

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$199k worth of stock

Consensus forecasts updated

Price target increased to US$17.67

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?